Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,709 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenic Disorders Clear all
Terminated Phase 2 Interventional Results available

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

NCT04421456
View directory record Official record
Conditions
Schizophrenia
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 9, 2026, 11:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Restoring Spindle and Thalamocortical Efficiency in Early-Course Schizophrenia Patients Using Auditory Stimulation

NCT05956951
View directory record Official record
Conditions
Schizophrenia
Interventions
Closed-loop auditory stimulation, Sham auditory stimulation
Device
Lead sponsor
Fabio Ferrarelli
Other
Eligibility
18 Years to 40 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional

L-carnosine for Schizophrenia

NCT00177177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
L-carnosine (dietary supplement)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

NCT04860830
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Anaheim, California • Culver City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 9, 2026, 11:38 PM EDT
Active, not recruiting Not applicable Interventional

Youth Nominated Support Team

NCT05558332
View directory record Official record
Conditions
Psychosis, Suicide, Health Care Utilization, Family Members
Interventions
Youth-Nominated Support Teams for CHR
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years to 25 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

NCT01031563
View directory record Official record
Conditions
Cocaine Dependence, Cannabis Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 11:38 PM EDT
Terminated Phase 2 Interventional Results available

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCT03132571
View directory record Official record
Conditions
Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions
Naltrexone, Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
PACE-Life, Exercise Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

NCT02970305
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 9, 2026, 11:38 PM EDT
Terminated Not applicable Interventional Results available

Antipsychotic Effects of Oxytocin

NCT01621737
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Irvine, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851
View directory record Official record
Conditions
Schizophrenia, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Glendale, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Social Cognition Intervention

NCT01267019
View directory record Official record
Conditions
Psychosis
Interventions
social cognitive training with in vivo augmentation, social cognitive training, non-social skills training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

NCT03356639
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP6981, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

NCT01385709
View directory record Official record
Conditions
Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)

NCT03769493
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Mobile After-Care Support (MACS) app
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Peer Support for Exercise in Older Veterans With Psychotic Disorders

NCT02958007
View directory record Official record
Conditions
Psychotic Disorder
Interventions
Peer Education on Exercise for Recovery, Enhanced supervised fitness training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 2 Interventional

Pharmacotherapy for Schizophrenic Drug Users - 6

NCT00000281
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders, Shcizophrenia
Interventions
Amantadine
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 9, 2026, 11:38 PM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Phase 3 Interventional

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00128479
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
44
States / cities
Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 9, 2026, 11:38 PM EDT
Completed No phase listed Observational

Antipsychotics and Blood Vessel Function

NCT00585273
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
Jess G. Fiedorowicz
Other
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 9, 2026, 11:38 PM EDT
Completed Not applicable Interventional Results available

Implementing mHealth for Schizophrenia in Community Mental Health Settings

NCT04147897
View directory record Official record
Conditions
Schizophrenia
Interventions
FOCUS
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Chehalis, Washington • Colville, Washington • Everett, Washington + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 9, 2026, 11:38 PM EDT